AU UCE azhageshwaran anna university.ppt

research

1. INTERVIEW FOR Ph.D. ADMISSION FOR JULY
2024 SESSION
Topic of Research type here
1

2. INTERVIEW FOR Ph.D. ADMISSION FOR JULY 2024 SESSION 2
Name of the Candidate:Mr.R.Azhagesh
Reference No. :242851013
Affiliation (for PT Scholars):
Name of the Proposed Supervisor:
Affiliation :

3. INTERVIEW FOR Ph.D. ADMISSION FOR JULY 2024 SESSION 3
Sl.No.DegreeSpecialisation
University/
Institute
Year of
Passing
Marks
(%/CGPA)
1
2
3

4. INTERVIEW FOR Ph.D. ADMISSION FOR JANUARY 2022 SESSION 4
Sl.
No.
DesignationOrganisation FromTo
Years of
Experience
1
2
3
Total Years of Experience

5. INTERVIEW FOR Ph.D. ADMISSION FOR JULY 2024 SESSION 5
Sl.
No.
Title of the
Paper
Authors
Name of
the Journal
Year, Volume,
Issue
Impact Factor as
per Clarivites
1
2
3
4
5
Note: Papers published till 30.04.2024 only will be considered

6. Pulmonaryinfectionsposeasignificantglobalhealthchallengeduetoconstant
exposureoftherespiratorytracttoairbornemicroorganisms.
Lowerrespiratorytractinfections,inparticular,arealeadingcauseofmortality
worldwideandamajorfinancialburdenonhealthcaresystems.
Theriseofmultidrug-resistant(MDR)bacteriaexacerbatesthesituation,
necessitatingthedevelopmentofnewtherapeuticstrategies.
Thisresearchaimstodevelopaninnovativeinhalable"nano-in-micro"drypowder
formulationincorporatingantimicrobialpeptides(AMPs),lipid-basednanocarriers,
anti-inflammatorynutrients,biosurfactants,andadditivestotreatpulmonary
infectiousdiseaseseffectively.
INTERVIEW FOR Ph.D. ADMISSION FOR JULY 2024 SESSION 6

7. Developandoptimizeaformulationfornasaldeliveryofatherapeuticpeptide
specificallydesignedfortreatingRDS.
Evaluatetheefficacyandsafetyoftheoptimizedformulationinrelevantpre-
clinicalmodels.
Investigatetheimpactofformulationstrategies,pharmaceuticalandbiological
considerationsonnasalpeptidedeliveryandtherapeuticeffectiveness.
INTERVIEW FOR Ph.D. ADMISSION FOR JULY 2024SESSION 7

8. Developmentofstableandeffectivenasalformulationfordeliveringa
therapeuticpeptidefortreatingRDS.
Demonstrateimprovedefficacyandsafetyofthenasalpeptidetherapy
comparedtoexistingoptions.
Provideinsightsintotheinfluenceofformulationstrategiesandbiological
considerationsonnasalpeptidedeliveryforRDStreatment.
INTERVIEW FOR Ph.D. ADMISSION FOR JULY 2024SESSION 8

9. INTERVIEW FOR Ph.D. ADMISSION FOR JULY 2024SESSION 9

10. INTERVIEW FOR Ph.D. ADMISSION FOR JULY 2024SESSION 10

11. INTERVIEW FOR Ph.D. ADMISSION FOR JULY 2024SESSION 11

12. Nasal Peptide
INTERVIEW FOR Ph.D. ADMISSION FOR JULY 2024SESSION 12

13. INTERVIEW FOR Ph.D. ADMISSION FOR JULY 2024SESSION 13

14. INTERVIEW FOR Ph.D. ADMISSION FOR JULY 2024 SESSION 14

15. Theproposedresearchisnovelinitsapproachtocombinetheadvantagesof
nano-andmicro-particlesforinhalationtherapy.Thisaimsto:
Enhancethestabilityandefficacy.
Achievetargeteddeliveryandsustainedreleaseinthelungs.
Addressbothantimicrobialresistanceandinflammationsimultaneously.This
innovativestrategyhasthepotentialtorevolutionizethetreatmentof
pulmonaryinfections,particularlythosecausedbyMDRbacteria,byimproving
therapeuticoutcomesandreducinghealthcarecosts.
INTERVIEW FOR Ph.D. ADMISSION FOR JULY 2024SESSION 15

16. INTERVIEW FOR Ph.D. ADMISSION FOR JULY 2024 SESSION 16

17. INTERVIEW FOR Ph.D. ADMISSION FOR JULY 2024 SESSION 17